Free Trial

Alterity Therapeutics (ATHE) Stock Price, News & Analysis

-0.03 (-1.76%)
(As of 12:17 PM ET)
Today's Range
50-Day Range
52-Week Range
2,350 shs
Average Volume
67,120 shs
Market Capitalization
$9.04 million
P/E Ratio
Dividend Yield
Price Target

Alterity Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
255.3% Upside
$7.00 Price Target
Short Interest
0.42% of Float Sold Short
Dividend Strength
News Sentiment
1.18mentions of Alterity Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.25) to ($0.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.37 out of 5 stars

ATHE stock logo

About Alterity Therapeutics Stock (NASDAQ:ATHE)

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

ATHE Stock Price History

ATHE Stock News Headlines

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
Alterity Therapeutics Limited (ATHE)
Alterity Therapeutics Ltd ADR ATHE
ATHE Alterity Therapeutics Limited
Alterity Therapeutics Ltd. ADR
See More Headlines
Receive ATHE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
$3.37 million
Book Value
$3.78 per share


Free Float
Market Cap
$9.20 million
Not Optionable
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Geoffrey Paul Kempler B.Sc. (Age 69)
    Co-Founder & Non-Executive Chairman
    Comp: $204.63k
  • Dr. David A. Stamler M.D. (Age 63)
    Chief Executive Officer
    Comp: $604.79k
  • Mr. Phillip Allen Hains BBus(Acc) (Age 65)
    C.A., M.B.A., CFO & Company Secretary
  • Dr. Rudolph Emile Tanzi Ph.D. (Age 65)
    Chief Scientific Advisor and Member of Research & Development Advisory Board
  • Dr. Steven D. Targum
    Chief Medical Advisor
  • Dr. Robert Cherny
    Head of Research

ATHE Stock Analysis - Frequently Asked Questions

Should I buy or sell Alterity Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alterity Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATHE shares.
View ATHE analyst ratings
or view top-rated stocks.

What is Alterity Therapeutics' stock price target for 2024?

1 brokerages have issued 1 year price objectives for Alterity Therapeutics' shares. Their ATHE share price targets range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 255.3% from the stock's current price.
View analysts price targets for ATHE
or view top-rated stocks among Wall Street analysts.

How have ATHE shares performed in 2024?

Alterity Therapeutics' stock was trading at $2.49 on January 1st, 2024. Since then, ATHE shares have decreased by 20.9% and is now trading at $1.9699.
View the best growth stocks for 2024 here

Are investors shorting Alterity Therapeutics?

Alterity Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 35,000 shares, a decrease of 59.3% from the April 30th total of 85,900 shares. Based on an average daily volume of 80,600 shares, the short-interest ratio is currently 0.4 days. Approximately 0.4% of the shares of the company are short sold.
View Alterity Therapeutics' Short Interest

When did Alterity Therapeutics' stock split?

Alterity Therapeutics's stock reverse split on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Alterity Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alterity Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).

How do I buy shares of Alterity Therapeutics?

Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATHE) was last updated on 5/30/2024 by Staff

From Our Partners